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ABSTRACT
Background: Glioblastoma (GBM) has a high rate of local recurrence despite 
chemoradiotherapy (CRT). Genome-wide expression profiling was performed on 
patient tumors before and after chemoradiotherapy to identify genes and gene 
pathways associated with recurrence.
Results: Median time to recurrence was 8.9 months with median time to second 
surgery of 9.6 months. The microRNA (miRNA) analysis identified 9 oncologic and 
immune-related miRNAs to be differentially expressed, including the hypoxia-related 
miR-210 and the immune-modulatory miR-146b. More than 1200 differentially-
expressed genes were identified with RNA-sequencing (RNA-seq). Gene set 
enrichment analysis (GSEA) identified p53 signaling, Notch, Wnt, VEGF, and MEK 
gene sets enriched in recurrent GBM. Consistent with the miRNA profiling data, the 
miR-146b target gene set from GSEA analysis was also associated with recurrence.
Methods: Fourteen patients with GBM recurrence after CRT who had available 
tumor tissue from the initial diagnosis as well as recurrence were selected. Total 
RNA was isolated from formalin-fixed paraffin-embedded (FFPE) tumor specimens. 
Genome-wide expression profiling using RT-PCR for miRNA analysis and RNA-seq for 
messenger RNA (mRNA) analysis were conducted to identify differentially-expressed 
genes. GSEA was performed on the differential expression data. 
Conclusions: Genome-wide expression profiling identifies multiple oncologic and 
immune-related gene sets associated with GBM recurrence. In particular, immune-
related miR-146b is upregulated in recurrence and deserves further investigation.
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INTRODUCTION
Glioblastoma (GBM, World Health Organizaiton/
WHO grade IV) is the most common malignant primary 
brain tumor in adults and has an annual incidence of 3.2 
in 100,000 in the United States [1]. Based on a large 
randomized study, adjuvant radiation therapy (RT) and 
temozolamide (TMZ) after maximal safe resection is the 
standard of care for GBM, but the outcomes remain dismal 
despite multi-modality therapy with median progression-
free survival (PFS) of 6.9 months and overall survival 
(OS) of 14.6 months [2]. Outcomes have improved in 
recent clinical trials with median OS of approximately 17 
months [3, 4]. Tumor recurrence occurs predominantly 
inside the radiation field rather than distantly [5], 
suggesting a subpopulation of GBM cells that are highly 
resistant to chemoradiotherapy (CRT). With recurrence, 
treatment is more limited and outcomes remain poor 
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[6]. Recent advances in immunotherapy have generated 
excitement in developing novel approaches to treat this 
devastating disease [7, 8]. For example, programmed-
death-1 (PD-1), an immune checkpoint surface receptor 
expressed on lymphocytes, has been implicated as a 
mediator of immune suppression by tumors such as 
GBM [8]. Nivolumab, an anti-PD-1 checkpoint inhibitor, 
is currently under investigation in two randomized 
studies for newly diagnosed GBM (NCT02617589 and 
NCT02667587). However, chemoradiotherapy for GBM 
can result in severe and prolonged lymphopenia that 
may contribute to tumor recurrence and interfere with 
future success of immunotherapy [9, 10]. Thus, there is a 
clear need to better understand the mechanisms of GBM 
resistance to CRT and its interaction with immune system, 
which will be crucial for the discovery of novel therapies 
for this devastating disease. However, due to the difficulty 
of access to GBM tissue, particularly recurrent tumor 
tissue, detailed molecular profiling to compare changes in 
tumors before and after CRT have been limited.
MicroRNAs (miRNAs) are a family of small non-
coding RNA molecules (~22 nucleotides) that regulate 
expression of thousands of protein-coding genes [11]. 
With the ability to regulate the expression of a large 
number of genes, miRNAs function as master regulators 
of important processes such as cell growth, apoptosis, 
cancer initiation and progression [12, 13]. Functional 
studies with modulation of certain miRNAs have 
demonstrated direct effects on glioma stem cell properties 
and sensitivity to CRT [14–17]. There is also increasing 
evidence that miRNAs play important regulatory roles 
on the immune pathways currently targeted by the major 
immunotherapeutic approaches, including immune 
checkpoint blockade, adoptive cell transfer, cancer 
vaccines, and cytokine therapy [18]. 
Given the importance of miRNAs, we hypothesized 
that miRNA expression changes in GBM after CRT may 
allow an improved understanding of pathways responsible 
for treatment resistance. We also employed a genome-wide 
expression profiling approach of 14 GBM tumors before 
CRT and their corresponding recurrent tumor after CRT to 
identify oncologic and immune-related changes within the 
recurrent tumors after CRT. 
RESULTS
Patients and outcomes
Fourteen patients were eligible for the analysis 
(Supplementary Table 1). There were 7 females and 7 
males included in this study. The mean age was 53 years. 
Patients received RT with concurrent temozolomide 
followed by adjuvant temozolomide from 2006-2012. The 
median dose to the planning target volume was 60 Gy. Two 
patients had placement of carmustine implants (Gliadel 
wafer; Eisai Inc) at the time of initial surgery and one 
patient received concurrent bevacizumab. After recurrence 
but before the second salvage surgery, three patients 
received salvage bevacizumab-based chemotherapy, and 
one patient received laser interstitial thermal therapy 
(LITT). Median time to progression was 8.9 months 
(range: 2.9–24.4). Median time to second surgery was 10.3 
months (3.4–32.9). Only one patient was alive at the time 
of this analysis. Median OS was 23.1 months (12.3–72.0). 
O6-methylguanine-DNA-methyltransferase (MGMT) 
methylation and isocitrate dehydrogenase (IDH) status 
were largely not assessed in this patient cohort.
miRNA profiling identifies oncologic and 
immune-related miRNAs
miRNA profiling was performed for the initial and 
recurrent tumors for all 14 patients. A real-time reverse 
transcriptase-polymerase chain reaction (RT-PCR) 
based miRNA profiling experiment revealed 9 miRNAs 
differentially expressed with statistical significance in 
recurrent GBM (Table 1). The miRNA with the greatest 
fold change was miR-210 (recurrence/initial ratio 1.91, 
p = 0.003), which has established roles in cell survival, 
particularly in hypoxic conditions [23]. miR-146b, which has 
been shown to be a critical mediator of immune-regulatory 
pathways [24, 25], was also upregulated (recurrence/initial 
ratio 1.55, p = 0.02). Table 1 also shows several select 
predicted targets of the miRNAs based on miRDB prediction 
(http://mirdb.org) [26], which correspond to oncologic and 
immune-related genes, including Notch2 [27], TGFBR1 
[28], STAT3 [29], FGFRL1 [30], and NOVA1 [31].
RNA-seq analysis
Given the multiple oncologic and immune-related 
miRNAs differentially expressed in recurrent GBM, a 
large-scale genome-wide expression profiling study using 
RNA-sequencing (RNA-seq) was employed to identify 
genes and gene pathways associated with recurrence. Due 
to limited RNA quality from two patients as well as the 
initial tumor of a third patient, RNA-seq was employed 
on 11 initial and 12 recurrent RNA samples. More than 
1200 genes were identified that were differentially 
expressed with statistical significance (p < 0.05) 
(Supplementary Table 2). Selected genes related to iron-
metabolism, oncologic pathways, and immune function 
are shown in Table 2, including transferrin (TF), ferritin 
(FTL), fibroblast growth factor 1 (FGF1), TNF receptor-
associated factor 4 (TRAF4), and signal transducer and 
activator of transcription 1 (STAT1).
GSEA implicates multiple oncologic and 
immune-related genes in recurrence
Given the significant number of genes differentially 
expressed, gene set enrichment analysis (GSEA) 
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Table 1: miRNA differentially expressed in recurrent high-grade glioma
miRNA Fold change p-value Select predicted targets (mirdb)
hsa-mir-210 1.91 0.003 IGF2, FGFRL1, AIFM3, CEND1
hsa-mir-191 1.44 0.005 TMOD2 (neuronal), MAPK9, CRCAM, CDK6, Notch2, DAPK1, TRAF3, BDNF
hsa-mir-101 1.66 0.005 TGFBR1, GLTSCR1
hsa-mir-126* 0.44 0.016 MACC1, MAP3K2, TNFAIP8L3, RASAL2, CCNT2, MAPK10, TRAF6
hsa-mir-96 0.33 0.018 MTSS1, SDC2, NEUROD4, MAP2K1, RAB35
hsa-mir-146b 1.55 0.024 ITPR2, RGS4, IL1A, NAV3, NOVA1, SRSF6
hsa-mir-25 0.72 0.024 CD69, JMY, RAB23, MYO1B, MAP2K4
hsa-mir-24 1.41 0.031 CALCR, AAK1, KSR2
hsa-mir-20a 0.69 0.034 MAP3K2, PDCD1LG2, AAK1, TNFRSF21, NEDD4L
Fold change represents the mean expression value of recurrent glioma divided by initial tumor. P-value calculated using a 
paired Student’s T-test.
Table 2: Select differentially-expressed genes in recurrent GBM   
Upregulated in recurrence
Gene name Gene symbol Relative expression P-value
transferrin TF 5.34 0.0085
interferon-induced protein with tetratricopeptide repeats 2 IFIT2 3.54 0.0006
apoptosis-associated tyrosine kinase AATK 3.38 0.0125
cyclin-dependent kinase 18 CDK18 3.30 0.0292
breast carcinoma amplified sequence 1 BCAS1 2.94 0.0221
microtubule-associated protein 7 MAP7 2.59 0.0101
fibroblast growth factor receptor 2 FGFR2 2.42 0.0400
ferritin, light polypeptide FTL 2.35 0.0025
fibroblast growth factor 1 FGF1 2.22 0.0058
signal transducer and activator of transcription 1 STAT1 2.08 0.0019
lysosomal-associated membrane protein 2 LAMP2 1.78 0.0008
Downregulated in recurrence
Gene name Gene symbol Relative expression P-value
neurocan NCAN 0.26 0.0433
glutamate receptor, ionotropic, AMPA 2 GRIA2 0.45 0.0334
fatty acid binding protein 7, brain FABP7 0.48 0.0236
ets variant 1 ETV1 0.49 0.0209
nestin NES 0.52 0.0370
TNF receptor-associated factor 4 TRAF4 0.53 0.0334
melanoma antigen family D, 4 MAGED4 0.54 0.0076
neuro-oncological ventral antigen 1 NOVA1 0.55 0.0330
P-values calculated using a two-sided Student’s T-Test
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was employed to identify pathways associated with 
recurrence. Using this statistical tool, recurrent GBM 
was noted to be enriched in gene sets associated with 
the MEK, KRAS, Notch, VEGF, and Wnt pathways, 
among others (Supplementary Table 3). Additionally, 
the gene sets associated with P53, iron metabolism, 
and interferon signaling were associated with GBM 
recurrence (Figure 1A–1D). Given the association 
between GBM recurrence and immune-related genes and 
gene sets, we explored the immunologic story further. 
Multiple immune-related gene sets were associated 
with recurrence (Figure 1C–1D and data not shown). 
Using the Leading Edge analysis in the GSEA statistical 
software package [22] (Figure 2A), an overlap region 
corresponding to multiple immune-related genes present 
in multiple enriched gene sets was identified (Figure 2B). 
Multiple immune-regulatory interferon-related genes as 
well as STAT1/2 (Signal Transducer and Activator of 
Transcription) in particular, which plays a key role in 
tumor progression [32–34] and immune-modulation [29, 
35–37], were present in this overlap region.
miR-146b gene set identified in GBM recurrence
We previously demonstrated increased expression 
levels of the immune-modulatory miRNA, miR-146b, 
in tumor tissue isolated from recurrent GBM (Table 1). 
Interestingly, GSEA analysis of all miRNA gene sets revealed 
that the gene set corresponding to miR-146b targets was 
found to be enriched in GBM recurrence (Figure 3). Multiple 
immune-related targets of miR-146b have been identified by 
miRDB prediction (http://mirdb.org). Supplementary Table 
4 shows several miR-146b target immune-related genes with 
decreased expression from the RNA-seq dataset comparing 
gene expression between recurrent and initial tumors, 
including Nova1, HNRNPD/AUF1A, and SNX22. 
Figure 1: Gene Set Enrichment Analysis (GSEA) in recurrent glioma. GSEA of differential expression between recurrent and 
initial high-grade glioma demonstrates that recurrent GBM is enriched in genes that participate in the p53 tumor suppressor pathway (A), 
heme metabolism (B) and interferon signaling (C–D). ES–enrichment score, NES–normalized enrichment score, FDR–false discovery 
ratio.
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miR-146b fold change associated with local 
recurrence
The median fold change of miR-146b between 
recurrent and initial tumors was 1.5 (range: 0.6–5.4). 
Low miR-146b change (ratio < 1.5) was associated with 
significantly improved freedom from salvage surgery ( 
FFSS) (Figure 4B, p = 0.01) and a trend toward improved 
freedom from local recurrence (FFLR) (Figure 4A, p = 0.06). 
However, the local control did not translate to significant 
difference on OS (p = 0.45, Figure 4C). Cox regression 
analysis (Supplementary Table 5) using miR-146b ratio as a 
continuous variable showed an association with time to local 
recurrence (hazard ratio [HR] 1.59, 95% confidence interval 
[CI] 1.007–2.52, p = 0.047) as well as time to salvage surgery 
(HR 1.68, 95% CI 1.06–2.69, p = 0.03), but not with time to 
death (HR 1.32, 95% CI 0.86–2.04, p = 0.21).
DISCUSSION
This pilot study compared miRNA and mRNA 
expression profiles of 14 pairs of GBM tumors before 
CRT and after recurrence. It identified several candidate 
oncologic and immune-related miRNAs and gene 
sets differentially expressed in recurrent GBM. In 
particular, the immune-modulatory miRNA miR-146b 
was significantly increased at recurrence and may be a 
promising target for future studies. Due to the difficulty 
after repeated biopsy of intracranial tumors, detailed 
expression profiling studies of miRNA and transcriptome 
(or RNA) of GBM tumors before and after CRT have been 
limited in the literature. Park et al. previously performed 
a miRNA analysis on 2 untreated GBM tumors and 2 
recurrent GBM tumors after CRT (from two different 
patients) where they identified 43 miRNAs with at least 
two-fold changes in expression levels in both of the 
recurrent tumors (miR-146b is not among them) [38]. 
However, given the recurrent and initial tumors were 
not from the same patients and the extremely limited 
sample size, it’s difficult to interpret this study’s findings. 
Bo et al. [39] analyzed the publically available miRNA 
profile data from 12 paired primary and recurrent GBM 
samples using microarrays. They noted that miR-146b 
was downregulated in the recurrent samples. However, 
the treatments of these 12 patients before their recurrences 
were not described, so there may be inherent differences 
between the patient populations. Furthermore, the 
discrepancy may be due to the differences in the miRNA 
profiling techniques. The PCR-based platform in the 
current study has shown greater detection specificity 
(at single-base level) than the microarray platform, and 
it is commonly used to validate microarray or RNA-
seq results. Other studies have conducted genome and 
exome sequencing of larger cohorts of paired initial and 
recurrent GBM tumors, but they did not specifically 
analyze miRNA expression changes [40, 41]. These 
Figure 2: Immune-related genes associated with recurrent glioma. Genes differentially expressed in recurrent gliomas enriched 
across multiple immunologic gene sets. Investigation of the top most enriched genes in the various immunologic gene sets from the GSEA 
(A) results in the boxed overlap region (B).
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studies paint complex pictures of mutation alterations and 
evolutionary trajectories of GBM tumors during CRT but 
do not explore the potential of common miRNA pathways 
in GBM resistance. The differentially higher expression 
of miR-146b in recurrent GBM found in our analysis of 
paired recurrent and initial GBM is in contradiction to 
investigations from Li et al. [42], Katakowski et al. [43], 
Liu et al. [44] and Yang et al. [45], who all demonstrated 
that overexpression of miR-146b in a GBM cell culture 
system reduces migration/invasion and increases apoptosis 
and radiosensitivity. These results need to be taken with 
the necessary caveats of an in vitro culture system which 
Figure 3: Immune-related gene set miR-146b associated with recurrent glioma. GSEA reveals gene set associated with 
targets of miR-146b associated with recurrent glioma, linking miRNA profiling results with RNA-seq gene expression analysis. ES–
enrichment score, NES–normalized enrichment score, FDR–false discovery ratio.
Figure 4: Clinical outcomes stratified by miR-146b expression ratio. Kaplan-Meier estimates of clinical outcomes stratified by 
high and low miR-146b ratios between recurrent vs initial tumors (A) freedom from local recurrence, (B) freedom from salvage surgery, 
and (C) overall survival.
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inherently lacks the complexity of GBM recurrence in 
vivo. Our hypothesis presented in this manuscript is that 
miR-146b upregulation in recurrence plays a role in GBM 
immune-suppression potentially at a later stage of the 
tumor progression event, ultimately resulting in tumor 
recurrence. This manuscript challenges the notion of miR-
146b functioning as solely a tumor suppressor. Based on 
our investigation of human GBM recurrent tumor tissue in 
relation to the paired initial tumor, the role of miR-146b in 
tumorigenesis, tumor progression, and tumor maintenance 
is likely more complex than has been previously reported 
in the literature. 
A vast number of potential targetable pathways in 
GBM have been identified in preclinical studies, but few 
have shown efficacy in the clinical setting. Complicating 
clinical efficacy is the heterogeneity of these tumors 
stemming from the complexity of their molecular makeup 
[41, 46]. This complexity is highlighted in the results 
presented in this study using a Gene Set Enrichment 
Analysis (GSEA) with recurrent GBM enriched in MEK, 
NOTCH, SRC, RAF, P53, VEGF, and WNT gene sets. 
Studies have shown redundant activation of numerous 
signaling pathways, which likely explains the futility of 
single-drug therapies [47]. 
This study implicates the immune-modulatory 
miRNA miR-146b as an important factor to drive 
GBM recurrence after chemoradiotherapy. Multiple 
studies have established an immune-modulatory role 
for miR-146b, including suppression of IL-6 allowing 
p16-dependent tumorigenesis in breast cancer [24], as 
well as suppression of multiple other pro-inflammatory 
cytokines and chemokines such as TNF-alpha, IL-
8, and IL-10 [25]. Park et al. implicated miR-146b 
in dendritic cell survival and cytokine production 
via targeting of TRAF6 and IRAK1 [48]. Lu et al. 
also recently showed that miRNA-146b are highly 
expressed in regulatory T cells (Tregs) and play a 
vital role in their expansion, survival, and suppressor 
function [49]. Since Tregs have been implicated as a 
major contributor to the evasion of immunosurveillance 
by GBM and are correlated with poor prognosis [50], 
our finding may be a reflection of the miRNA changes 
of the infiltrating immune cells within the tumor 
microenvironment rather than the tumor cells. Our 
gene expression results highlight several established 
miR-146b immune-modulatory targets, including 
HNRNPD/AUF1A and SNX22 (Supplementary Table 
4). HNRNPD/AUF1A is a nuclear ribonucleoprotein 
with roles in NF-kB signaling and interleukin 
expression [51]. SNX22 has been shown through 
its role in endocytosis to down-regulate CD4 [52]. 
As immunotherapy continues to develop for GBM, 
an improved understanding of the role of miR-146b 
may help to develop novel approaches to overcome 
the high level of immune suppression by the GBM 
microenvironment [53–55]. 
Since this study is a small pilot study of genome-
expression profiling, its findings need to be interpreted 
with the following limitations. As this study is based on 
a limited sample size and a highly selected population 
of GBM patients who underwent salvage surgery for 
recurrence after CRT, the finding should be considered 
hypothesis-generating. The small sample size limits 
the use of stringent FDR-controlling method. External 
validation using a larger sample size, ideally using a multi-
institutional tumor bank, will be necessary to confirm 
our finding. Recent data have also shown significant 
regional and cellular heterogeneity within GBM [56, 57]. 
Therefore, the expression profiling of our samples may 
only represent snap-shots of the complex composition of 
the tumor cells and tumor-infiltrating immune cells, and 
other methods such as single-cell RNA-seq to compare 
tumor cells before and after treatment will be needed to 
provide validation in the future. Furthermore, our study 
does not prove causality that the expression change 
of miR-146b represents the mechanism driving the 
recurrence rather than passive treatment-induced changes. 
Functional studies in vitro and in vivo will be needed to 
further confirm the role of miR-146b in promoting GBM 
recurrence.
In conclusion, this study presents multiple 
deregulated miRNAs and gene pathways after CRT 
and implicates the immune-modulatory miR-146b 
as a potential factor in GBM recurrence. Additional 
investigations are warranted to validate the association 




Eligible patients with pathologically diagnosed 
GBM were identified from our institutional review board 
(IRB)–approved database. They were required to have 
received standard fractionated RT and concurrent daily 
TMZ at 75 mg/m2 after maximal safe resection. These 
patients were also required to have sufficient pathologic 
tissue from the initial surgery before CRT and the salvage 
surgery at the time of recurrence after CRT. Additional 
salvage chemotherapies were allowed prior to the salvage 
surgery. This study was reviewed and granted approval by 
the IRB.
RNA isolation from tumor specimens
Formalin-fixed paraffin-embedded (FFPE) tumor 
blocks from the initial and salvage surgeries were 
collected for pathological analysis. FFPE specimens were 
stained with hematoxylin and eosin (H&E), reviewed 
by a board-certified neuro-pathologist (CC) to confirm 
diagnosis and to demarcate tumor regions. This was 
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followed by macrodissection of 10-micron unstained 
sections in order to remove non-tumor tissues. Total 
RNA was then extracted using the miRNeasy FFPE Kit 
(Qiagen) according to the manufacturer’s protocol.
miRNA profiling
miRNA expression profiling of 96 miRNAs 
implicated in tumorigenesis was performed using our 
laboratory’s previously described method, which is based 
on RT-PCR, the details of which have been described 
previously [19]. The RT reaction was performed with 
the High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems, Foster City, CA). Each RT reaction 
included 150 ng of tumor RNA and miRNA-specific RT 
primers. RT-PCR was performed with Power SYBR 
Green PCR Master Mix (Applied Biosystems) and 
miRNA-specific PCR primers. Raw profiling data based 
on PCR threshold cycles (Ct) were normalized using a 
quantile-based scaling method, which has been described 
previously [19].
RNA-seq for gene expression profiling in 
recurrent and initial GBM
RNA-seq was performed to allow identification 
and quantification of expression of genes in a given 
tumor sample by a single massively parallel sequencing 
run [20]. Details of the experimental protocol has 
been described previously [21]. Total RNA was used 
to construct multiplexed cDNA libraries, which were 
provided to the Genome Technology Access Center 
(GTAC) at Washington University School of Medicine 
for sequencing. Ribosomal RNA (rRNA) was removed 
using the RiboMinus kit (Life Technologies) and custom 
designed rRNA probes. rRNA-depleted total RNA was 
used as template for RNA-seq library construction using 
the NEBNext mRNA Library Prep kit (New England 
BioLabs). Double-stranded cDNA was synthesized 
from rRNA-depleted total RNA, end-repaired, dA-
tailed, and then ligated to standard Illumina adaptor 
oligonucleotides. Adaptor-ligated cDNA libraries were 
loaded into HiSeq 2000 (Illumina) for sequencing. Raw 
RNA-seq data (in fastq format) were made available after 
the sequencing runs, which were parsed to align each 
sequence read to the original RNA sample. Sequencing 
reads were modified to remove low quality reads and 
clustered before mapping to the human transcriptomes. 
Gene expression levels were normalized using a strategy 
based on the length of the transcript as well as the 
number of total read counts from each sample (reads per 
kilobase per million, RPKM).
Gene Set Enrichment Analysis (GSEA)
Differential gene expression profiles were generated 
using RNA-seq from recurrent GBM (n = 12) and the 
initial tumor (n = 11). Utilizing GSEA software available 
from the Broad Institute [22], gene sets with member 
genes enriched in recurrent GBM were discovered. 
Statistically significant gene sets were considered with 
p-value < 0.05 and FDR (false discovery ratio) < 0.25. 
ES (enrichment score) reflects the degree to which a gene 
set is over-represented in our dataset of differentially 
expressed genes. NES (normalized enrichment score) is 
the ES normalized for gene set size.
Statistical analysis
All time points were determined from the date 
of initial surgery. Statistical significance (p < 0.05) for 
differential expression was calculated using the Student’s 
T-test. Median value of the fold change in miR-146b 
expression in recurrent vs initial tumors was used as 
cutoff to identify high fold change (mir-146b ratio ≥ 1.5) 
vs low fold change (mir-146b ratio < 1.5). Freedom from 
local recurrence (FFLR), freedom from salvage surgery 
(FFSS), and overall survival (OS) were evaluated using 
the Kaplan-Meier method and compared using the log-
rank test. Cox regression analysis was utilized to evaluate 
the association of miR-146b fold change with clinical 
outcomes. Statistical analyses were performed with the 
Statistical Package for Social Sciences, version 22 (IBM 
SPSS Statistics, Chicago, IL, USA). Significance was 
defined as a p value ≤ 0.05. All statistical tests were two 
sided.
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